Plenty of women are told that if hormone therapy is off the table, there is nothing much to be done about hot flashes. That was never entirely true, and in the last few years it has become clearly false.
The reason is that we now understand the mechanism well enough to target it directly.
What actually causes a hot flash
Your brain defends a narrow range of core body temperature. Inside that range, nothing happens. Above it, you sweat and your skin vessels dilate. Below it, you shiver.
As estrogen falls, that range narrows. A small rise in core temperature that would have meant nothing at 40 now reads as overheating, and your body responds with a full heat-dumping reflex — flushing, sweating, then the chill afterward as it overshoots.
The specific circuitry involves a group of hypothalamic cells called KNDy neurons. Estrogen normally restrains them. Without that restraint they enlarge and signal more, releasing neurokinin B onto the neighbouring thermoregulatory center.
That is not a theory offered after the fact. It is the target two new drug classes were built around.
The newest options: neurokinin receptor antagonists
Fezolinetant blocks the neurokinin 3 receptor. In phase 3 randomized trials it reduced the frequency and severity of moderate to severe hot flashes compared with placebo, and it is FDA-approved for that indication. It is a once-daily tablet and contains no hormone at all.
The practical catch is liver monitoring. Liver blood tests are checked before starting and periodically afterward, and it is not used in women with cirrhosis or severe kidney impairment. That is a schedule we set up before you start, not something to discover later.
Elinzanetant blocks both the neurokinin 1 and neurokinin 3 receptors. It also reduced hot flash frequency and severity against placebo in phase 3 trials, with trial data additionally showing improvement in sleep disturbance — which for a lot of women is the symptom that actually ruins their life.
Neither is as effective as estrogen on average. Both produce real, substantial reductions. For a woman who has had breast cancer or a blood clot, “less effective than the option you cannot have” is not a meaningful criticism.
Cost and coverage are the other real-world issue. These are expensive and coverage varies. We check before you leave and we handle prior authorization ourselves.
The older options, which still work
Low-dose paroxetine (7.5 mg) is the only non-hormonal product FDA-approved specifically for hot flashes. Important caveat: it is not used with tamoxifen, because it inhibits the enzyme that converts tamoxifen into its active form.
Venlafaxine and escitalopram are used off-label with good randomized trial support. They are a sensible choice when low mood or anxiety needs treating as well, which is common.
A note, because women ask this every time: at these doses you are not being treated as if you are depressed. These medications act on neurotransmitter systems that also influence temperature regulation. That is the effect being used.
Gabapentin has randomized trial support and is sedating, which makes it particularly useful when night sweats are the dominant problem. Taken at bedtime, it can address both the sweats and the sleep.
Oxybutynin has randomized trial support for hot flashes, and is also used for bladder urgency — so it can do two jobs. The tradeoff is anticholinergic burden, which we weigh carefully in women over 65 given the observational data linking high cumulative anticholinergic exposure with cognitive risk.
Cognitive behavioral therapy, which is underused
CBT deserves more attention than it gets, and it needs to be described accurately.
CBT does not reliably reduce how many hot flashes you have. What it reduces is how much they interfere with your life — the bother, the anticipatory anxiety, the dread before an episode, the disruption. Trials consistently show that.
For insomnia, CBT-I has better evidence than any sleep medication and, uniquely, its benefit persists after treatment ends. If your main problem is lying awake rather than the flashes themselves, this may be the highest-yield thing available to you, and it is available through digital programs as well as in person.
What about supplements
Black cohosh, evening primrose oil, soy isoflavones, and similar products have been studied. The trials have been small, inconsistent, and largely negative, and results have not held up in larger studies.
We do not recommend them as treatment. We do want to know if you are taking them, because supplements are not manufactured to prescription standards and several interact with prescription medications.
Lifestyle measures are a different category. Avoiding personal triggers, layering clothing, keeping the bedroom cool, moderating alcohol and caffeine — these genuinely help some women and they cost nothing. They are worth doing. They do not usually control moderate to severe symptoms on their own, and telling a woman waking six times a night that she should try layering is not a treatment plan.
How we choose between them
We start with what else is going on.
Depression or anxiety alongside hot flashes points toward an SSRI or SNRI. Night sweats dominating points toward gabapentin at bedtime. Bladder urgency alongside points toward oxybutynin, with the cognitive question weighed. Tamoxifen rules out paroxetine and fluoxetine. Wanting the most effective non-hormonal option for hot flashes specifically points toward a neurokinin antagonist.
Then we set a defined trial — usually 8 to 12 weeks — and a way to measure it. You log hot flash frequency and a symptom score in the app. At the end we compare numbers rather than impressions.
If it did not work, we say so and change it. Most women not helped by the first non-hormonal option are helped by a second. What we will not do is quietly add a third prescription to two that are not doing anything.
The bottom line
“You can’t take hormones” is not the end of the conversation. It is the start of a different one, with real options in it.